Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events

ABSTRACT

A composition and a method of treatment for the reduction of risk factors for cardiovascular disease utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of PCT/US2012/025003, filedFeb. 14, 2012, which claims benefit of priority to U.S. ProvisionalPatent Application Ser. No. 61/457,268, filed Feb. 16, 2011, thecontents of which are incorporated herein by reference in theirentireties.

FIELD OF THE INVENTION

The present invention relates to combinations of one or more cholesterolabsorption inhibitors, such as ezetimibe, with mixtures of omega-3 fattyacid compositions designed to mediate omega-3 deficiencies inindividuals in need thereof; and to methods of administering suchcombinations, and to unit dosages of such combinations for the reductionof circulating cholesterol levels in cardiovascular disease patients(CVD). The invention particularly relates to compositions wherein theomega-3 formulation is designed to mediate omega-3 deficiencies inindividuals in need thereof; particularly to compositions containingspecific ratios of highly purified long chain fatty acid compositionswhich are effective in elevating omega-3 levels to a point at which therisk factors for cardiovascular disease are mitigated, and mostparticularly to a composition having an EPA:DHA ratio and level ofomega-3 purity which enable them to be effective in providing asustained vasodilatory effect, defined as a vasodilatory effect lastingat least 6 hours.

BACKGROUND OF THE INVENTION

Cardiovascular disease (CVD) represents the primary cause of mortalityfor men and women in developed countries globally. These prematuredeaths come at great cost to both the individuals and their families, aswell as representing a huge burden to the health care system of thecountry. The risk factors for coronary heart disease are well-recognizedand include: higher than average serum cholesterol, elevated levels ofLDL; a low level of HDL in proportion to the LDL level; higher thanaverage serum triglycerides; and higher levels of lipid oxidationproducts creating plaques and streaks which cause blockages of coronaryarteries. An additional risk factor for coronary heart disease andstroke is high blood pressure. Reduction in these risk factors iseffective to reduce the prevalence of coronary heart disease and itsmany costs.

In humans, cholesterol and triglycerides are part of the totallipoprotein complexes present in the bloodstream, characterized ashigh-density lipoprotein (HDL), intermediate-density lipoprotein (IDL),low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL)fractions.

Cholesterol and triglycerides are synthesized in the liver, incorporatedinto VLDL, and released into the plasma. High levels of totalcholesterol (total-C), LDL-C, and apolipoprotein B (a membrane complexfor LDL-C) promote human atherosclerosis and decreased levels of HDL-Cand its transport complex, apolipoprotein A, which are associated withthe development of atherosclerosis. Cardiovascular morbidity andmortality in humans can vary directly with the level of total-C andLDL-C and inversely with the level of HDL-C. Cholesterol absorptioninhibitors are known (see for example Rosenblum, S. B., et al., J. Med.Chem., 41(6):973-80 (1998)).

Although in some cases, genetic predisposition contributes to CVDincidence, poor diet and sedentary lifestyle are major factors thatcontribute to increased risk for the development, and progression ofCVD. Because of this, clinical management of CVD often includes anattempt to modify a patient's lifestyle to increase exercise, andincorporate a balanced diet, rich in omega-3 fatty acids. Due tonon-compliance, and often an inability of a patient to adhere tolifestyle modifications, optimal patient care is not achieved throughthese efforts alone, and other therapeutic interventions or strategiesmust be considered.

Treatment options may include lipid-regulating medications, such asstatins, or fibrates that act to lower low density lipoprotein (LDL)cholesterol and/or triglycerides (TG), metabolic components that arethought to contribute to atherosclerotic plaque buildup, and increasethe risk for heart attack or stroke. Additional therapies may includethe use of lipid-lowering compounds that selectively inhibit theintestinal absorption of cholesterol. However, many of these treatmentoptions come with unwanted side effects that could add additional healthrisks, or cause physical discomfort.

Azetidinone-based compounds, e.g. ezetimibe, are an example ofcholesterol absorption inhibitors (see Bioorg. Med. Chem.,7(10):2199-202 (1999)). Ezetimibe is in a class of lipid-loweringcompounds that selectively inhibits the intestinal absorption ofcholesterol and related phytosterols. It is a white, crystalline powderthat is freely to very soluble in ethanol, methanol, and acetone andpractically insoluble in water. The chemical name is(3R,4S)-1-(p-fluorophenyl)-3-[(3S)-3-(p-fluorophenyl)-3-hydroxypropyl]-4-(p-hydroxyphenyl)-2-azetidinone(6)and the molecular formula is C₂₄H₂₁F₂NO₃. It is marketed under suchtradenames as EZEDOC, EZEE, EZET, EZETIB, EZZICARD, LIPEZET, ZETICA,EZTA, and EZIBLOC.

In the field of CVD prevention, there is no single prior art compositionwhich reduces the variety of risk factors associated with this pervasivedisease and which has wide spread applicability to the population indeveloped countries.

In one aspect, the present invention provides a novel composition, whichmay be incorporated into an orally administered dietary regimen for thereduction of risk factors associated with CVD. The composition of theinvention represents a unique combination of one or more cholesterolabsorption inhibitors with an omega 3 fatty acid formulation.

In accordance with the findings of the U.S. 2005 Dietary GuidelinesAdvisory Committee, 70% of Americans are omega-3 fatty acid deficient.Further studies indicate that over 84% of CVD patients are deficient inomega-3 fatty acids, specifically Eicosapentaenoic acid (EPA),Docosahexaenoic acid (DHA) and Docosapentaenoic acid (DPA).

Omega-3 fatty acids are natural polyunsaturated fats found in sea foodslike fish and which are presently also available as dietary supplements.They contain more than one double bond in the aliphatic chain. They arenamed according to the number (>1), position and configuration of doublebounds. The three major types of omega-3 fatty acids are alpha-linolenicacid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).These omega-3 polyunsaturated fatty acids have been shown to protectagainst several types of cardiovascular diseases such as myocardialinfarction, arrhythmia, atherosclerosis, and hypertension (Abeywardenaand Head, 2001; Kris-Etherton et al., 2003). It is widely accepted that(EPA) (C20:5n-3) and (DHA) (C22:6n-3) are the major biological activepolyunsaturated fatty acids contributing to the prevention of a varietyof cardiovascular disorders by improving endothelium-dependentvasodilatation and preventing activation of platelets. Fish oil, EPA andDHA have been shown to induce relaxation and inhibit contraction bymechanisms which are endothelium-dependent (Shimokawa et al., 1987;Yanagisawa and Lefer, 1987). High contents of omega-3 polyunsaturatedfatty acids, especially EPA, inhibited platelet aggregation andincreased bleeding time, presumably due to a reduced generation ofthromboxane A₂. Previous studies have also shown that dietarysupplementation with cod-liver oil purified omega-3 fatty acidspotentiated endothelium-dependent relaxations in isolated porcinecoronary arteries (Shimokawa et al., 1988).

If a combination therapy including a novel omega-3 formulation incombination with one or more cholesterol absorption inhibitors, could beprovided for enhancing the patient's lipid profile and mitigating thevarious risk factors for cardiovascular disease, particularly reductionof overall serum cholesterol levels, reductions in high blood pressureand pulse rate, increase in the HDL:LDL ratio, reduction oftriglycerides and homocysteine levels, lowering of the activity of theblood coagulation factor VII-phospholipid complex, and prevention oflipid oxidation and the formation of plaques, a long felt need would berealized.

SUMMARY OF THE INVENTION

The prior art fails to disclose a pharmaceutical formulation as setforth in the instantly disclosed invention, containing the combinationof a cholesterol absorption inhibitor and an omega-3 compositioncontaining about 90% or greater omega 3 fatty acids by weight having acombination of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid(DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sumof the EPA, DHA and DPA is about 82% by weight of the total formulationand about 92% of the total omega 3 fatty acid content of thecomposition. EPA+DHA are about 80% of the total formulation and about89% of the total omega 3 fatty acid content of the composition. Incombination, each of these components, which independently reduce one ormore of the risk factors for cardiovascular disease (CVD), are expectedto work synergistically to reduce the risk of CVD more effectively thanany of these components taken alone.

It is noteworthy that tailoring the ratios, content and purity of omegafatty acid formulations provides the skilled artisan with a significantset of specific parameters, whereby formulations having a desiredutility or pharmacological action may be derived.

The present inventors have discovered that the ability of omega-3 fattyacid preparations to cause endothelium-dependent relaxations depends ontheir relative content of EPA and DHA, as well as the purity of theoverall formulation and the presence of additional key omega-3 fattyacids, particularly DPA.

Indeed, formulations in accordance with the present invention having anEPA:DHA ratio of about 6:1 induced significantly greater relaxationsthan an EPA:DHA 1:1 preparation despite their similar content of omega-3fatty acids. These findings also suggest that EPA is likely to be a morepotent endothelium-dependent vasorelaxant agonist than DHA. The factthat the two major omega-3 fatty acids do not have similar biologicalactivity to cause endothelium-dependent relaxation is important sincethe leading commercial omega-3 preparations (Lovaza®) has a ratio ofEPA:DHA 1.2:1. Thus, the optimization of the ratio of EPA:DHA in omega-3preparations may provide new products with an enhanced vascularprotective potential.

The present invention provides a novel composition, which may beincorporated into an orally administered formulation for the reductionof risk factors associated with CVD, and a novel treatment method. Acomposition of the formulation of the invention may be used orally totreat and/or prevent risk factors of CVD and stroke, including reductionof high blood pressure and improving overall lipid profiles, e.g. lowdensity lipoprotein (LDL), high density lipoprotein (HDL) andtriglycerides. While not wishing to be bound by theory, the inventorsbelieve that the compositions work by acting at different sites andaspects of cardiovascular disease. The compositions of the presentinvention are preferably presented for administration to humans andanimals in unit dosage forms, such as tablets, capsules, pills, powders,granules, and oral solutions or suspensions and the like, containingsuitable quantities of an active ingredient.

The present invention also provides methods of treatment, for exampleadministering to a patient having an omega-3 fatty acid deficiency, thatmay be evidencing one or more risk factors for CVD, a therapeuticallyeffective amount of a formulation in accordance with the invention toachieve a therapeutic level of omega-3; whereby mitigation of said oneor more risk factors for CVD is achieved. In embodiments, the inventionis also a method for providing a sustained vasodilatory effect in apatient by administering a therapeutically effective amount of aformulation in accordance with the invention, whereby anindomethacin-independent sustained vasodilatory effect is achieved.

By providing a method of treatment for mediating omega-3 deficiencies,use of the instant invention to improve the health of the heart and toreduce risk factors associated with cardiovascular disease by deliveringto an individual the composition of the invention is realized. Deliveryof the composition of the invention, e.g., by oral administration, hasbeen shown to be useful for preventing oxidation of low densitylipoprotein (LDL), increasing high density lipoprotein (HDL), and forreducing total cholesterol. Delivery of the composition of the inventionis also useful for reducing triglycerides and reducing homocysteine.

Desirably, the compositions of the invention are formulated such that aneffective amount is delivered by multiple tablets (or other suitableformulation) a day. Suitably, these doses may be taken with meals, mixedinto food, or taken on an empty stomach. Generally improvement isobserved after two to eight weeks of daily use. Optionally, thecompositions of the invention may be delivered daily in a suitable form(e.g., a chew or bar). Other suitable dosage regimens may be readilydeveloped by one of skill in the art. Such dosage regimens are not alimitation of the invention. The compositions of the present invention,in addition to their use in treating CVD in humans, may also be usefulin treating non-human animals, particularly mammals. For example, thesedietary supplements may be useful for companion animals such as dogs andcats, for cattle, horses, and pigs, among other animals.

A primary objective of the instant invention is to teach a combinedtherapy comprising a cholesterol absorption inhibitor and an omega-3fatty acid formulation. The combined therapy may be supplied either assingle dosage forms or in a combined dosage form. One or morecholesterol absorption inhibitors are useful in the treatment ofpatients with hypertriglyceridemia, hypercholesterolemia, mixeddyslipidemia, atherosclerotic disease, coronary heart disease (CHD) andcardiovascular disease (CVD). Exemplary, albeit non-limiting examplesare ezetimibes marketed under such tradenames as EZEDOC, EZEE, EZET,EZETIB, EZZICARD, LIPEZET, ZETICA, EZTA, and EZIBLOC or pharmaceuticallyacceptable salts thereof or a combination thereof. These cholesterolabsorption inhibitors are provided along with mixtures of an omega-3fatty acid formulation containing a minimum of 90% omega 3 fatty acidsby weight including a combination of Eicosapentaenoic acid (EPA) andDocosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight ofthe total formulation and about 92% of the total omega 3 fatty acidcontent of the composition. EPA+DHA are about 80% of the totalformulation and about 89% of the total omega 3 fatty acid content of thecomposition.

The fatty acids of the present invention are understood to includebiologically active glyceride forms, e.g. triglycerides, biologicallyactive ester forms, e.g. ethyl ester forms, and biologically activephospholipid forms, their derivatives, conjugates, precursors, andpharmaceutically acceptable salts and mixtures thereof. It is understoodthat the combination of omega-3 formulation and cholesterol absorptioninhibitors may be provided as a single unit dosage form, or as separateand distinct unit dosage forms.

A further objective of the instant invention is to teach methods ofadministering such combinations, and unit dosages of such combinationsfor the treatment of hypertriglyceridemia, hypercholesterolemia, mixeddyslipidemia, atherosclerotic disease, and vascular disease incardiovascular disease patients (CVD), whereinby these risk factors arelowered significantly.

It is a further objective of the instant invention to provide a methodand system for its practice to mediate omega-3 deficiency in patientshaving a need therefore, while assisting such patients in improvingtheir lipid profile by the co-administration of a cholesterol absorptioninhibitor and an omega 3 fish oil.

These and other advantages of this invention will become apparent fromthe following description taken in conjunction with any accompanyingdrawings wherein are set forth, by way of illustration and example,certain embodiments of this invention. Any drawings contained hereinconstitute a part of this specification and include exemplaryembodiments of the present invention and illustrate various objects andfeatures thereof. All examples are illustrative and non-limiting in viewof the disclosure.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates the study design for the VASCAZEN™ open label study;

FIG. 2 is a plot of improved whole blood EPA+DHA+DPA levels baseline toweek 6;

FIG. 3 illustrates the normal distribution curves for Groups A-C duringthe Open Label Study;

FIG. 4 illustrates the effect of differing EPA:DHA ratios on therelaxation of coronary artery rings with and without the presence of theendothelium;

FIG. 5 discloses the relaxation effect of an EPA:DHA 6:1 control versusthe effect of eNOS and EDHF inhibitors;

FIG. 6 discloses how the presence of Src kinase and PI3-kinase impactsthe relaxation effect of an EPA:DHA 6:1 product;

FIG. 7 illustrates the shift in relaxation effect of an EPA:DHA 6:1product by membrane permeant analogues;

FIG. 8A illustrates the effect EPA:DHA 6:1 has on both Akt and eNOSphosphorylation;

FIG. 8B illustrates Western Blot Data Showing Sustained eNOS Activationof Vascazen at 6 hours at a Concentration of 0.4% and 40 μg of Protein;

FIG. 9 demonstrates the relation of purity to the sum of EPA+DHArelative to total Omega-3 ratios on the relaxation of coronary arteryrings in the presence or absence of endothelium;

FIG. 10 illustrates that the relaxation effect of the subject EPA:DHA6:1 formulation is insensitive to the presence of indomethacin;

FIG. 11A and FIG. 11B illustrate the indomethacin sensitivity of therelaxation effect of the subject EPA:DHA 6:1 formulation relative toseveral over the counter Omega-3 products;

FIG. 12 illustrates the indomethacin sensitivity of the relaxationeffect of the EPA:DHA 6:1 formulation relative to a formulation of likeratio containing certain additives;

FIG. 13 illustrates the comparative vasorelaxing effect of EPA:DHA 6:1according to the present invention as compared to EPA:DHA 1:1, EPA aloneand DHA alone;

FIG. 14 illustrates the mechanism by which EPA:DHA 6:1 stimulates theendothelial formation of NO via the redox-sensitive activation of thePhosphoinositide 3-Kinase (PI3-Kinase)/Protein Kinase (Akt) pathway.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a combination therapy and a method forits use which contains novel combinations of selected mixtures of one ormore cholesterol absorption inhibitors with an omega 3 fatty acidformulation.

The methods are useful in the treatment of patients withhypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia,atherosclerotic disease, cardiovascular disease (CVD) and vasculardisease.

The oral administration of these compositions acts to reduce serumcholesterol levels and blood pressure, increase HDL levels in proportionto LDL levels, to protect lipids from oxidation thereby preventing theformation of plaques which block coronary arteries, and to lower bothtriglyceride levels and homocysteine levels. In addition, it is believedthat oral administration of the compositions of this invention acts toreduce the risk of stroke, as well as heart attack, in human adults.

One particularly desirable embodiment of the invention is directedtoward a composition and a method for its use including a cholesterolabsorption inhibitor, which is exemplified by, albeit not limited to anezetimibe marketed under such tradenames as EZEDOC, EZEE, EZET, EZETIB,EZZICARD, LIPEZET, ZETICA, EZTA, EZIBLOC, or pharmaceutically acceptablesalts thereof or a combination thereof; and an omega-3 fatty acidformulation.

With respect to the omega-3 component of the combination therapy andmethod of its use, the present invention provides a long chain fattyacid composition that includes a formulation containing a minimum ofabout 90% omega 3 fatty acids by weight having a combination ofEicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) in a weightratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA andDPA is about 82% by weight of the total formulation and about 92% of thetotal omega 3 fatty acid content of the composition. EPA+DHA are about80% of the total formulation and about 89% of the total omega 3 fattyacid content of the composition. The fatty acids of the presentinvention are understood to include biologically active glyceride forms,e.g. triglycerides, biologically active ester forms, e.g. ethyl esterforms, and biologically active phospholipid forms, their derivatives,conjugates, precursors, and pharmaceutically acceptable salts andmixtures thereof.

The pharmaceutical formulation of the instant invention is contemplatedas being administered in amounts providing a daily dosage of 1 to 4 gmof said formulation. The pharmaceutical formulation at such dosage levelbeing effective for the treatment or prophylaxis of risk factors ofcardiovascular disease and the protection against sudden death inpatients with CVD.

Pharmaceutical formulations of the instant invention may be providedwherein a unit form is a gel or liquid capsule.

An exemplary unit dosage form includes from about 645 to about 715 mg/gmEPA, for example about 680 mg/gm EPA and from about 105 to 115 mg/gm,for example about 110 mg/gm DHA. The unit dosage can include from about22 to about 28 mg/gm DPA for example about 25 mg/gm DPA. Unit doses mayadditionally include a stabilizer, e.g. tocopherol in amounts up toabout 0.5%, for example about 0.15% to about 0.25% or about 0.2% byweight. The effective unit dosage is generally 3 gm to 4 gm of thepharmaceutical formulation which are provided daily to CVD patients inone or more unit doses, for example about 3-4 one gram capsules per day.As set forth below, one or more optional ingredients can be included inthe formulations. Such ingredients may be separately added or may becomponents of the source from which the omega 3 fatty acids in theformulation are derived.

In some embodiments, the formulation may further contain about 30 mg/gmof arachidonic acid (AA). In some embodiments, the formulation mayfurther contain up to about 5%, for example about 3% or about 30 mg/gmof arachidonic acid (AA). It has been discovered that aspirin-acetylatedCOX-2 is also able to convert Omega-6 AA through lipoxygenases (LOX) tolipoxins (LXs), which are potent anti-inflammatory mediators (NatureChemical Biology, Vol. 6, June 2010, Pp 401-402).

Some embodiments of the formulation contains >2%, for example >3%, of 18carbon Omega-3 fatty acids, either individually or in total. Exemplary18 carbon atom omega-3 include alpha-linolenic acid (ALA) andStearidonic acid (SDA), either alone or in combination. Studies haveshown that the presence of 18 carbon Omega-3s, such as ALA elicitanti-inflammatory effects (Zhao et al, Am J Clin Nutr 2007; 85:385-91).The composition is formulated with a specific amount of DHA consistingof about 400 mg per daily dose.

The composition can contain additional fatty acids in lesser amounts,usually less than about 1% of each that is present. Exemplaryembodiments contain about 0.3-0.7%, or about 5% of any of the additionalfatty acids, These additional fatty acids can include, for example,omega-6 fatty acids such as Dihomo-gamma-linolenic acid (DGLA; 20:3n6),Docosapentaenoic acid (Osbond acid; 22:5n6); omega-9 fatty acids such asOleic acid (18:1n9) and others such as 7,10,13,15-hexadecatetraenoicacid and (16:4n1), 9,12,15,17-octadecatetraenoic acid (18:4n1). Otherfatty acids may be present in higher quantities. For example,Eicosatetraenoic acid (ETA; 20:4n3) may be present in amounts up toabout 2%, for example about 1.5%, and Heneicosapentaenoic acid (HPA;21:5n3) may be present in amounts up to about 3%, for example at about2.3%. These additional fatty acids may be added separately or may bepresent in formulations obtained from particular sources usingparticular methods. Other additional components and fatty acids may alsobe present in small amounts, for example 0-0.25% of the formulation.

The composition is formulated with a DHA content to provide about 400 mgper daily dose.

Daily administration of the formulation can reduce the level oftriglycerides (TG) and increases high density phospholipids (HDL)levels, while lowering low density lipoprotein (LDL) levels in CVDpatients.

A highly potent omega-3 formulation in accordance with the presentinvention is marketed by Pivotal Therapeutics, Inc., under the tradename VASCAZEN™, to alleviate the cardiovascular risks associated withomega-3 deficiency. VASCAZEN™, has been formulated for the dietarymanagement of omega-3 deficiency in patients with CVD, providing EPA andDHA to levels not attainable through normal dietary modifications. Morespecifically, the VASCAZEN™ product exemplifies the present invention inbeing composed of about 90% or more omega-3 fatty acids at a ratio ofeicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) within therange of 5.7:1-6.3:1, respectively. The formulation contains about 680mg/g of EPA, about 110 mg/g of DHA, and about 25 mg/g of DPA percapsule. Each capsule has a total weight of about 1000 mg. It isgenerally contemplated that a daily regimen of VASCAZEN™ includes 4tablets per day given either in one dose or in separate doses throughoutthe day. With respect to a 1000 mg fill, the formulation contains atleast about 90% or more omega-3 fatty acids, wherein about 80% is thesum of EPA+DHA, and about 82% the sum of EPA+DPA+DHA. Embodiments canalso contain about 30 mg/g of arachidonic acid, an omega-6 fatty acid,and/or >3% of 18 carbon Omega-3 fatty acids.

The present invention provides a novel composition, which may beincorporated into an orally administered formulation for the reductionof risk factors associated with CVD, and a novel treatment method. Acomposition of the formulation of the invention may be used orally totreat and/or prevent risk factors of CVD and stroke, including reductionof high blood pressure and improving overall lipid profiles, e.g. lowdensity lipoprotein (LDL), high density lipoprotein (HDL) andtriglycerides. While not wishing to be bound by theory, the inventorsbelieve that the compositions work by acting at different sites andaspects of cardiovascular disease. The compositions of the presentinvention are preferably presented for administration to humans andanimals in unit dosage forms, such as tablets, capsules, pills, powders,granules, and oral solutions or suspensions and the like, containingsuitable quantities of an active ingredient.

The daily dose of formulated composition provides a stronganti-inflammatory and mood enhancing effect with a specific amount ofDHA for the protection against sudden death in patients with CVD.

According to a US study, and the Dietary Guidelines Committee, 70% ofAmericans are omega-3 deficient due to lack of consumption of thisessential nutrient in the typical “western diet”, which includes anoverabundance of pro-inflammatory omega-6 fatty acid intake, bycomparison. In patients with CVD, this dietary trend can be particularlydangerous. Coupled with other cardiometabolic risk factors, omega-3deficiency further exacerbates the chronic progression of this disease.A growing body of evidence has demonstrated the cardiovascular healthrisks associated with chronic omega-3 deficiency. A dietary deficiencyof EPA acid and DHA in particular, allows for downward pro-inflammatorypressures created by the metabolism of arachidonic acid (AA) that istypically very high in the diets of most Americans. Overall, omega-3fatty acid deficiency contributes to a pro-inflammatory state, theconsequences of which include negative effects on cardiovascular health,including increased risk for development of dyslipidemia (highcholesterol, high triglycerides), atherosclerotic plaque buildup,hypertension, and cardiac arrhythmia.

Chronic omega-3 deficiency can subsequently lead to increased risk forsuffering a fatal heart attack. Maintenance of blood levels of EPA, DHAand DPA above 6.1% of total blood fatty acids, compared to levelsbetween 2.1%-4.3% is associated with an 80.0% lower risk of suddencardiac death. To counterbalance the cardiovascular risks associatedwith an overabundance of AA, and the pro-inflammatory influences uponthis metabolic pathway, one would need to increase EPA and DHAconsumption to levels that can not be attained through dietary changesalone. Filling the “omega-3 nutritional void” thus requires additionalsupplementation with a highly potent EPA and DHA formulation, whichprovides high levels of EPA, as well as DHA, for full clinical benefit,removing a key risk factor in patients with CVD.

Example

In order to determine the presence of synergy attributable to theingestion of a combined therapy including the novel omega-3 fatty acidcomposition of the present invention and a cholesterol absorptioninhibiting pharmacologically active ingredient, the followingexperimental protocol will be carried out.

All patients will undergo drug therapy as required to treat theirclinical symptoms including the use of other classes ofcholesterol-lowering drugs like statins (that will not interfere withintestinal cholesterol levels).

One group of patients will be those who in addition to their existingdrug therapy are prescribed VASCAZEN™ following a protocol as set forthin the Open Label trial discussed herein, in combination with ezetimibeto lower circulating cholesterol concentrations.

A second group of patients will be those who are not prescribedezetimibe as part of their normal course of therapy, but are prescribedVASCAZEN™.

A third group will be prescribed ezetimibe alone, with no VASCAZEN™therapy.

Blood samples will be taken from all patients at the study baseline. Allpatients will be fasting for 12 hours prior to the blood sample beingtaken. After 6 weeks a second blood sample will be taken. This willdetermine if the drug intervention of ezetimibe alone, VASCAZEN™ aloneor a combination of ezetimibe and VASCAZEN™ influenced the circulatingcholesterol concentration.

In the previously conducted open label study to analyze the safety andefficacy of VASCAZEN™, whole blood omega-3 fatty acid levels wereexamined in 143 patients, and the inventive formulation was administeredto patients for two or six-week follow-ups, providing about 2800 mg/dayEPA and about 480 mg/day DHA. The primary outcome measure was the changein the sum of blood EPA+DHA+DPA. levels (the Omega-Score™), expressed asa percentage of total blood fatty acid levels over a two or six-weekduration.

The normalized baseline Omega-Score™ was 3.4% (N=143). In the two-weekand six-week treated groups, the inventive formulation increasedOmega-Score™ levels by 52.8% (N=63, p=<0.0001) and 120.6% (N=31,p=<0.0001) respectively, compared to baseline levels measured in eachgroup. After six weeks of intervention, maximal, and stable levels weremaintained at an average score of 7.5%. The formulation in accordancewith the present invention was generally well tolerated, with only minoradverse events reported in a small proportion of study participants.(See Table 4)

Methodology:

The 6-week open label study was conducted at a single site in Canada.Subjects were eligible for the study if they met all inclusion andexclusion criteria set out in the clinical study protocol. All eligiblesubjects provided informed consent prior study enrollment, and enteredGroup A (FIG. 1.). Sixty three subjects were provided 4 capsules per dayof VASCAZEN™ (Group B), an oral dose of 2720 mg EPA and 440 mg DHA perday. After two weeks of treatment, whole blood omega-3 blood level wasassessed, and 31 subjects entered into Group C, for continued treatment.Group C subjects provided whole blood samples at weeks 4 and week 6, forfollow-up Omega-Score™ assessment.

The primary outcome measure was the change in Omega-Score™ valuesexpressed as a percentage of total blood fatty acid levels over a 2-weekperiod for Group B, and 6-week period for Group C. The baselineOmega-Score™ value for Group A was calculated as the mean percentage atweek 0, prior to VASCAZEN™ intervention, and Groups B and C Omega-Score™means were evaluated at the specified time points accordingly.

The study included both men and women >15 years of age, in stablemedical condition. Exclusion criteria included the following: A historyof ventricular arrhythmia, known bleeding or clotting disorder, liver orkidney disease, autoimmune disorder or suppressed immune systems,seizure disorder or taking anticonvulsant medication; allergies to fish;or subjects with an implantable cardioverter defibrillator. Medicalhistories, and current medications were also documented.

Laboratory analysis of total blood fatty acids in whole blood wasconducted by a central laboratory, (University Health NetworkLaboratory, Toronto, Ontario), accredited by the College of AmericanPathologists' Laboratory Accreditation Program. Analysis was carried outby derivatizing fatty acids into methyl esters followed by GasChromatography-Mass Spectrometry (GC-MS) analysis (Agilent Technologies6890N series gas chromatograph, 5975C detector, Mississauga, Ontario).Fatty acids were extracted from 200 μL of whole blood sample using amixture of methanol and chloroform. Fatty acids were then methylatedwith 10% (w/v) BCl₃ in methanol by incubation at 90° C. for 25 min toform fatty acid methyl esters (FAMEs). After cooling the FAMEs wereextracted with water/hexane mixture and 1 uL of n-hexane extract wasinjected for GC-MS analysis.

Sample size was justified accordingly. Assuming a mean baseline level ofblood Omega-Score™ levels of at least 3.0% and a standard deviation inchange of blood Omega-Score™ levels of 1.8% in the study population, theminimum sample size of 63 study subjects would result in a minimum powerof 90.2% to detect an increase in blood Omega-Score™ levels following 2weeks of study intervention of at least 25.0% relative to baseline, at asignificance level of α=0.05. The minimum sample size of 30 subjectstaking VASCAZEN™ for six weeks would result in a minimum power of 94.2%to detect an increase in blood Omega-Score™ levels following 6 weeks ofstudy intervention of at least 40.0% relative to baseline, at asignificance level of α=0.05. The safety population was defined as apatient group that had a minimum of 2 weeks and maximum of 6 weeksVASCAZEN™, at a dose of 4 capsules per day. Primary analyses oftreatment efficacy was performed on the subset of enrolled studysubjects for whom blood measurements were taken at baseline and after 2weeks of study treatment. The change in blood Omega-Score™ levels overthe 2-week period (expressed as a percentage change from baseline) wascomputed for each study subject. The distribution of changes in bloodOmega-Score™ levels over 2 weeks were tested for normality using thePearson-D'Agostino test. A paired t-test was conducted in order to testthe change in blood Omega-Score™ levels over the 2-week period.

Secondary analyses of treatment efficacy was performed on the subset ofenrolled study subjects for whom blood Omega-Score™ levels were taken atbaseline and at time points of 2 weeks, 4 weeks and 6 weeks followingbaseline. An analysis of variance (ANOVA), utilizing subjects as blocks,was conducted to test the change in blood OmegaScore™ levels between anypair of time points over the 6-week period; multiple comparisons wereconducted at a family-wide significance level of α=0.05 in order todetermine which pairs of time points (if any) differ significantly interms of mean blood EPA+DHA+DPA levels. A linear contrast was carriedout in order to test the hypothesis that mean blood EPA+DHA+DPA levelsincrease linearly within this subset of study subjects over the 6-weekperiod.

Results:

Baseline characteristics of each study group are outlined in Table 1.Across all groups, age demographics were comparable, with the majorityof study participants being middle-aged. Within group A, the mean age ofthe total group (N=143), consisting of mostly males (74.1%), was 50.9years, and similar age distributions were observed between men (52.1),and women (46.9). Group B (N=63, 74.2% men), the two-week treatmentgroup, had a mean age of 53.7, with comparable mean ages between men(55.8) and women (47.9). Finally, study subjects within group C(N=31,87% men) had a mean age of 55.0 years (men, 54.0; women, 61.5). BaselineOmegaScore™ values were measured and all three groups, including men andwomen were found to have comparable, omega-3 deficient (defined as lessthan 6.1% Omega-Score) (N Engl J Med, Vol. 346, No. 15, Apr. 11, 2002,Pp. 1113-1118), scores between 3.3% and 3.8%.

TABLE 1 Baseline Characteristics*: Group A Characteristic  Men (N = 106)Women (N = 37) Total (N = 143)  Age, mean 52.1 ± 13.6 46.9 ± 15.0 50.9 ±14.6 (SD) (years) *Omega- Score ™(%) Mean 3.4 ± 1.4 3.5 ± 1.2 3.4 ± 1.395% CI 3.2 to 3.7 3.2 to 3.7 3.2 to 3.6 (±1.1 to 1.6) (±1.0 to 1.4)(±1.1 to 1.6) Group B Characteristic Men (N = 47) Women (N = 16) Total(N = 63) Age, mean 55.8 ± 10.9 47.9 ± 16.7 53.7 ± 13.1 (SD) (years)*Omega- Score ™(%) Mean 3.8 ± 1.4 3.3 ± 1.3 3.6 ± 1.3 95% CI 3.4 to 4.12.9 to 3.7 3.2 to 3.9 (±1.0 to 1.8) (±0.9 to 1.7) (±1.0 to 1.7) Group CCharacteristic Men (N = 27) Women (N = 4)  Total (N = 31) Age, mean 54.0± 8.7  61.5 ± 11.0 55.0 ± 9.2  (SD) (years) *Omega- Score ™(%) Mean 3.7± 1.2 N/A 3.4 ± 1.2 95% CI 3.3 to 4.0 N/A 3.1 to 3.7 (±0.8 to 1.5) (±0.8to 1.5) Omega-Score ™ calculated as the mean +/− SD (where N = number ofsubjects) from a normal distribution of raw data. Group C (women) didnot have sufficient numbers to fit a normal distribution curve. The meanbaseline score of the raw data for this group was 2.98%.

Results of the primary outcome measure are illustrated in FIG. 2 andTable 2, and calculated/fit to a normal distribution in FIG. 3, Table 3.Baseline levels of whole blood omega-3 blood levels revealed an omega-3deficiency (group A) in a large study group (N=143). Within this group,subjects had a mean score of 4.4%, or 3.4% (normal distribution curvefit), representing 84.5% of individuals with scores below a 6.1% scorecutoff, cardiovascular disease risk quartile. Study participants thatreceived VASCAZEN™ intervention for 2 weeks (group B) had a significant(P<0.0001) improvement in their scores (FIG. 2, Table 2), with meanvalues improving from 3.6% to 5.5% (FIG. 3, Table 3), a 52.8% scoreincrease. Over two weeks of intervention, study participants considered“at risk” were reduced from 80.6% to 46.8% (Table 3). Over the course of6 weeks VASCAZEN™ intervention, group C subjects had significant meanscore improvements (P<0.0001) (FIG. 2, Table 2), with mean valuesimproving from 3.4% to 7.5% between baseline and week 6 (FIG. 3, Table3), and representing a 120.6% increase in whole blood levels ofEPA+DHA+DPA Omega-Score™ values. After 6 weeks of VASCAZEN™intervention, 13.2% of participants remained at higher risk (<6.1%Omega-Score™), Table 3.

TABLE 2 Table 2. Primary Outcome Measure: Change in the sum of bloodEPA + DHA + DPA levels expressed as a percentage of total blood fattyacid levels over a two or six-week intervention Omega-Score ™ Mean ± SD(%) (% change from baseline) Group A (N = 143) Baseline 4.4 ± 1.7 GroupB (N = 63) Baseline 4.7 ± 1.9 Week 2 6.7 ± 1.9 (52.8%) Group C (N = 31)Baseline 4.3 ± 1.5 Week 2 6.4 ± 2.1 (48.8%) Week 4  8.6 ± 2.4 (100.0%)Week 6 8.2 ± 2.0 (90.7%)

TABLE 3 Table 3. Primary Outcome Measure: Change in the sum of bloodEPA + DHA + DPA levels expressed as a percentage of total blood fattyacid levels over a two or six-week intervention, and represented as anormal distribution. Omega-Score ™ (%) Mean ± SD % of Patients At (%change Risk (<6.1% from baseline 95% CI Omega-Score ™) Group A (N = 143)Baseline 3.4 ± 1.3 3.1 to 3.7 84.5% (±0.9 to 1.4) Group B (N = 63)Baseline 3.6 ± 1.3 3.2 to 3.9 80.6% (±1.0 to 1.7) Week 2 5.5 ± 1.6 5.1to 6.0 46.8%  (52.8%) (±1.2 to 2.1) (−33.8%) Group C (N = 31) Baseline3.4 ± 1.3 3.1 to 3.7 84.5% (±0.9 to 1.4) Week 2 5.7 ± 1.9 5.4 to 6.343.2%  (67.6%) (±1.4 to 2.3) (−41.3%) Week 4 7.9 ± 2.4 6.6 to 9.1 15.0%(132.4%) (±1.2 to 3.7) (−69.5%) Week 6 7.5 ± 1.2 7.0 to 8.0 13.2%(120.6%) (±0.7 to 1.7) (−71.3%)

Patients with >6.1% (ideal) scores had an 80% less chance of death fromsudden cardiac arrest, compared to individuals in the 2.1%-4.3% riskquartile (score) range. In this study, the mean baseline value of thestudy population indicated that 84.5% of study participants, many ofwhich with cardiovascular health issues, on statin, and/or bloodpressure medication, had scores less than 6.1%, leaving themselves atgreater risk for adverse events, especially in patients with knowndyslipidemia, type 2 diabetes, and/or hypertension. After six weeks ofVASCAZEN™ intervention, 71.3% of group C participants with previousbaseline scores less than 6.1% were able to increase their score to alevel above this threshold.

TABLE 4 Adverse Event 2-6 Weeks Treatment Relationship to Description (N= 63) Severity Study Treatment Reflux/Aftertaste 2 Mild Definite MinorLeg Bruising 1 Mild Unrelated* *Minor bruising appeared after two weeksof treatment and disappeared within 3 days. The subject continued takingVASCAZEN ™ for additional four week without any adverse event.

Group B study participant scores significantly increased (P<0.0001) by52.8% from 3.6% to 5.5%. With prolonged VASCAZEN™ intervention, group Cindividuals had significant score improvement over the course of 6 weeks(P<0.0001, ANOVA), with similar improvements as the group B individualswithin two weeks. After 4 weeks, VASCAZEN™ significantly (P<0.0001)increased mean scores from 3.4% to 7.9%, representing a 132.4%improvement, bringing the mean score of the total population to wellwithin the >6.1% low risk quartile. Indeed, only 15% of studyparticipants remained below this benchmark level after 4 weeks, a levelthat is sustained in the study group through 6 weeks of VASCAZEN™intervention. VASCAZEN™ was generally well tolerated with a lowincidence, of minor adverse events that are typical for omega-3polyunsaturated fatty acid ethyl esters. This study has highlighted theprevalence of chronic omega-3 deficiency in the majority of people(84%), both men and women.

The consequences of omega-3 deficiency in patients with CVD are welldocumented, with numerous studies linking EPA and DHA deficiency. Manystudies and current therapeutic approaches have categorized omega-3 as atherapeutic agent for the treatment of symptoms that accompany CVD.Unfortunately the common thread of thought around omega-3 fatty acidtherapy does not lead to optimal results. EPA and DHA should not beconsidered therapeutic agents, rather, they should be consideredessential nutrients, which should ideally be consumed regularly as partof a healthy balanced diet. Omega-3 deficiency in patients with CVD addsunnecessary risks, that can be avoided with suitable omega-3supplementation. The present invention as exemplified by VASCAZEN™intervention provides essential balanced levels of EPA and DHA that aredifficult for many CVD patients to incorporate into their daily dietthrough food alone. In the typical western diet, the average Americanconsumes 15 times less omega-3 fatty acids from fish than what isrequired to attain and maintain clinically beneficial levels of EPA andDHA. In order to consume enough of this essential nutrient to providethe daily dose that the present invention can provide, one would have toeat fish every single day, for more than one meal per day. This isunrealistic for most people.

The present study has demonstrated that maintenance of EPA+DHA+DPA tolevels >6.1% can be achieved with the present invention within 4 weeksof intervention, and that over 85% of patients can achieve these levelsat a dose of 4 capsules per day, supplying about 2720 mg EPA and 440 mgDHA. These findings support the use of omega-3 fatty acid supplementsaccording to the present invention for the maintenance of routinelymeasured (via Omega-Score™ assessment), clinically beneficialEPA+DHA+DPA blood levels in patients with CVD.

Sustained Vasodilatory Effect:

In addition to the benefits outlined above with respect to omega-3supplementation for an omega-3 deficient patient population,formulations according to the invention have been shown to provide asustainable eNOS vasodilatory effect, defined as a vasodilatory effectpersisting for 6 hours or more, which has heretofore not been achievablewith either prescription or OTC grade omega-3 supplements.

To understand this vasodilatory effect in the context of treatment andprevention of cardiovascular disease, it is first necessary tounderstand the mechanism of vasodilation via the endothelium lining ofblood vessels.

The following list of Abbreviations will be relied upon for thefollowing discussion.

ABBREVIATION LIST

Abbreviation Signification [Ca²⁺] i Intracellular free calciumconcentration APA Apamin CaM Calmodulin CaMK-2 Calmodulin kinase-2 cAMPCyclic adenosine 3′: 5′ monophosphate cGMP Cyclic guanosine 3′: 5′monophosphate EDHF Endothelium-derived hyperpolarizing factor eNOSEndothelial NO synthase ET-1 Endothelin-1 H₂O₂ Hydrogen peroxide IKCaCalcium-dependent Intermediate conductance Potassium Channels IndoIndomethacin L-NA N-ω-nitro-L-arginine MnTMPyP Mn (III) tetrakis(1-methyl-4-pyridyl) porphyrin NO Nitric oxide O₂° - Superoxide anionPEG-Catalase Polyethylene glycol-catalase PGI₂ Prostacyclin I2 PI3-KPhosphoinositide-3 kinase PKC Protein kinase C PP24-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4] pyrimidine ROSReactive oxygen species (Reactive Oxygen Species) sGC Soluble guanylylcyclase SKCa Ca²⁺-dependent small conductance potassium channels SODConductance Superoxide dismutase TRAM34 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole TX_(A2) Thromboxane A2 U466199,11-dideoxy-9-prostaglandin F2 methanoepoxy

The endothelium consists of a single endothelial cell layer lining theluminal surface of all blood vessels. Endothelial cells play animportant function in the regulation of vascular homeostasis. Theyregulate the contact of blood with the underlying thrombogenic arterialwall. They respond to numerous physiological stimuli such as circulatinghormones and shear stress by releasing several short-lived potentendothelium-derived vasoactive factors such as nitric oxide (NO) andendothelium-derived hyperpolarizing factor (EDHF), these two factorsplaying a major role in the control of vascular tone (Busse et al.,2002; Michel and Feron, 1997). In addition, endothelial cells can alsogenerate prostacyclin (PGI₂), a prostanoid causing relaxation of someblood vessels.

Endothelium-Derived Nitric Oxide (NO):

NO is produced by endothelial nitric oxide synthase (eNOS) fromL-arginine, NO plays critical roles in normal vascular biology andpathophysiology. NO induces relaxation of the vascular smooth muscle byactivating soluble guanylyl cyclase resulting in the formation of cyclicguanosine 3′-5′ monophosphate (cGMP). In addition to the regulation ofvascular tone and inhibition of platelet aggregation, NO also inhibitsmany key steps involved in atherogenesis including vascular smoothmuscle cell proliferation, monocyte adhesion (Dimmeler et al., 1997;Hermann et al., 1997; Tsao et al., 1996) and cell death. eNOS can beactivated by receptor-dependent and -independent agonists as aconsequence of an increase in the intracelluar concentration of free Ca([Ca²⁺]i) and the association of a Ca²⁺/calmodulin (CaM) complex witheNOS leading to its activation (Fleming et al., 2001). Indeed both theagonist-induced NO formation and subsequent vasorelaxation are abolishedby the removal of Ca²⁺ from the extracellular space as well as by CaMantagonists. eNOS is also regulated in endothelial cells at apost-translational level primarily through protein/protein interactionsand multisite phosphorylation at Ser116, Thr497, Ser635, and Ser1179(residue numbers are for the bovine sequence, equivalent to Ser114,Thr495, Ser633, and Ser1177 in the human sequence (Bauer et al., 2003;Boo et al., 2002; Dimmeler et al., 1997). Indeed, eNOS has been shown tobe regulated by the interaction with positive and negative proteinmodulators such as caveolin (Cav-1) and heat shock protein 90(Garcia-Cardena et al., 1998; Ju et al., 1997; Pritchard et al., 2001).In the basal state, the majority of eNOS appears to be bound tocaveolin-1 with its enzymatic activity being repressed in the caveolae(Michel et al., 1997). This tonic inhibition of eNOS can be released bydisplacing caveolin-1 with Ca²⁺/CaM in response to Ca²⁺ mobilizingagonists (Ju et al., 1997). In addition to these modulators,phosphorylation of eNOS at key regulatory sites plays an important arole in the regulation of enzyme activity in response to severalphysiological stimuli (Ju et al., 1997). It has been shown thatphosphorylation of eNOS at Ser1179 is associated with increased enzymeactivity (Gallis et al., 1999; McCabe et al., 2000). Phosphorylation ofeNOS-Ser1179 is regulated by PI3-kinase-dependent mechanisms (Gallis etal., 1999). Akt, one of the major regulatory targets of PI3-kinase, hasbeen shown to directly phosphorylate eNOS at Ser1179 and activate theenzyme in response to vascular endothelial growth factor (VEGF),sphingosine-1-phosphate, and estrogens (Dimmeler et al., 1997; Fulton etal., 1999). However, eNOS-Ser1179 can also be phosphorylated byAMP-activated protein kinase (Busse et al., 2002), protein kinase A(PKA), and protein kinase G (PKG). Exactly which protein kinase(s)phosphorylates eNOS-Ser1179 in intact cells appears to be dependent onthe type of endothelial cells and stimuli. For example, shear stressphosphorylates eNOS Ser1179 by a PI3-kinase- and PKA-dependent mannerwithout involving Akt whereas EGF phosphorylates eNOS Ser1179 by aPI3-kinase- and Akt-dependent manner (Boo et al., 2002). In addition,the ischemia-reperfusion injury activates the PKA pathway leading to thephosphorylation of eNOS at Ser1179 and Ser635 (Li et al., 2010). Inaddition, the level of eNOS expression can be modulated by severalfactors including shear stress (Butt et al., 2000), hypoxia, low-densitylipoproteins (LDL) (Chen et al., 2008; Chen et al., 1999) and oxidizedfatty acids (Corson et al., 1996).

Endothelium-Derived Hyperpolarizing Factor (EDHF):

Endothelium-dependent vasorelaxation has also been observed in someblood vessels following inhibition of NO and PGI2 synthesis and has beenattributed to endothelium-derived hyperpolarizing factor (EDHF). EDHFrelaxes blood vessels through hyperpolarization of the vascular smoothmuscle. This effect will close voltage-operated Ca²⁺ channels resultingin reduction of the intracellular free Ca²⁺ level and subsequentrelaxation of the vascular smooth muscle. Potassium (K⁺) channelsunderlie the hyperpolarization induced by EDHF and involve intermediateconductance Ca²⁺-activated K⁺ (IKCa) channels and small conductanceCa²⁺-activated K⁺ (SKCa channels). In several disease conditionsincluding the presence of cardiovascular risk factors, the endotheliumundergoes functional and structural alterations and it loses itsprotective role, and becomes proatherosclerotic (Vanhoutte, 1989). Theloss of the normal endothelial function is referred to as endothelialdysfunction, which is characterized by impaired NO bioavailabilitysubsequent to a reduced generation of NO by eNOS and/or an increasedbreakdown of NO by reactive oxygen species (ROS) and, in particular,superoxide anions (Vanhoutte, 1989).

Previous studies by the present inventors have indicated that naturalproducts such as Concord grape juice (Anselm et al., 2007) and red winepolyphenols (Ndiaye et al., 2005) activate the endothelial formation ofNO by causing the redox-sensitiveSer/PI3-kinase/Akt pathway-dependentphosphorylation of eNOSat Ser1177.

Fish oil omega-3 is a rich source of EPA and DHA. Omega-3 fatty acidshave been shown to cause endothelium-dependent vasorelaxation in vitroin rat aortic rings and coronary artery rings by stimulating theendothelial formation of NO (Engler et al., 2000; Omura et al., 2001).However, the signal transduction pathway leading to eNOS activationremains poorly studied. Moreover, little information is currentlyavailable regarding the optimal ratio of EPA:DHA for the activation ofeNOS. Therefore, the following experiments were carried out tocharacterize the fish oil-induced activation of eNOS in isolated bloodvessels and cultured endothelial cells.

The initial experiment was designed to determine the ability of omega-3fatty acids (EPA, DHA and different ratios of EPA:DHA) to causeendothelium-dependent relaxations in rings of porcine coronary arteries,thereby enabling the characterization of the role of NO and EDHF inendothelium-dependent relaxation and identification of the signaltransduction pathway involved.

Additional experiments were designed to determine the ability of omega-3fatty acids (EPA, DHA and different ratios of EPA:DHA) to causeactivation of eNOS in cultured endothelial cells and to determine theunderlying signal transduction pathway.

In order to make the above determinations we designed an experiment tocodify vascular reactivity. Initially, the left circumflex coronaryartery harvested from fresh pig hearts is cleaned of its fat andadherent tissue and cut into rings 2 to 3 mm in length. Rings withoutendothelium were obtained mechanically by rubbing with a pair of pliersinserted into the vessel lumen. Rings with or without endothelium weresuspended in organ baths containing Krebs bicarbonate solution(composition in mM: NaCl 118.0, KCl 4.7, CaCl₂ 2.5, MgSO₄ 1.2, NaHCO₃23.0; KH₂PO₄ 1.2 and glucose 11.0, pH 7.4, 37° C.) oxygenated with amixture of 95% O₂ and 5% CO₂. After equilibrating rings for 90 min at abasal tension of 5 g, rings were contracted with KCl (80 mM) to verifythe responsiveness of the vascular smooth muscle. After a 30 min washingperiod, the integrity of the endothelium was verified. Rings werecontracted with U46619 (1-60 nM, an analogue of thromboxane A2) to 80%of the maximal contraction, and at the plateau of the contraction,bradykinin (0.3 μM) was added to check the presence of a functionalendothelium. After repeated washings and return to baseline, rings werecontracted again with U46619 before applying an increasing range ofomega-3 fatty acids (0.001% to 0.4% v/v) to test their ability to inducerelaxation of coronary artery rings. During the stabilization phase (30min before contraction with U46619) different pharmacological tools wereadded to the Krebs bicarbonate solution to characterize the signalingpathway leading to endothelium-dependent relaxations:

a. Indomethacin (10 μM), an inhibitor of cyclooxygenases (COX) toprevent the formation of vasoactive prostanoids, particularlyprostacyclin,

b. Nω-nitro-L-arginine (L-NA, 300 μM), a competitive inhibitor of NOsynthase (NOS) to overcome the NO component, and

c. TRAM 34 (100 nM) and apamin (100 nM) inhibitors of Ca²⁺-activatedpotassium channels (IKCa and SKCa) respectively, to overcome the EDHFcomponent.

Pig coronary artery endothelial cells were harvested, cleaned withphosphate buffered saline solution (PBS) without calcium to remove anyresidual blood. Endothelial cells were isolated by collagenase (type I,Worthington, 1 mg/ml, 14 min at 37° C.) and cultured in medium MCDB131(Invitrogen) supplemented with 15% v/v fetal calf serum, 2 mM glutamine,100 U/mL penicillin, 100 U/mL streptomycin and 250 mg/ml fungizone(Sigma, St Louis, Mo.) at 37° C. in 5% CO₂. All experiments wereperformed with confluent endothelial cells used at first passage.Endothelial cells were exposed to MCDB131 with 0.1% v/v fetal calf serum5 h before treatment with different substances.

After treatment, endothelial cells were rinsed twice with PBS and lysedwith extraction buffer (composition in mM: Tris/HCl 20, pH 7.5(QBiogene), NaCl 150, Na₃VO₄ 1, Na₄P₂O₇ 10, NaF 20, okadaic acid 0.01(Sigma), protease inhibitors (Complete Roche) and 1% Triton X-100). 25μg of total proteins were separated on SDS-polyacrylamide (Sigma 8%) at100 V for 2 h. Separated proteins were transferred onto a polyvinylidenefluoride membrane (Amersham) by electrophoresis at 100 V for 2 h. Themembranes were blocked with blocking buffer containing 3% bovine serumalbumin in TBS-T (Tris-buffered saline solution, Biorad, containing 0.1%Tween 20, Sigma) for 1 h. For detection of proteins, membranes wereincubated in TBS-T containing the respective primary antibodies (p-eNOSSer 1177, p-eNOS Thr 495 and p-Akt Ser 473 (dilution 1:1000), β-tubulin(dilution 1:5000, Cell Signaling Technology) overnight at 4° C. After awashout period, the membranes were incubated with secondary antibodies(anti-rabbit for p-eNOS, p-Akt, and anti-mouse for β tubulin) coupled tohorseradish peroxidase (Cell Signaling Technology, dilution 1:5000) atroom temperature for 1 h. Stained protein markers (Invitrogen) were usedfor the determination of the molecular weight of separated proteins.Immunoreactive bands were detected using chemiluminescence (Amersham).

All results were presented as mean±standard error of mean (SEM). nindicates the number of different coronary arteries studied. Statisticalanalysis was performed using Student t test or analysis of variance(ANOVA) test followed by Bonferoni post-hoc test. A P value of <0.05 isconsidered statistically significant.

Results:

The omega-3 fatty acid preparation EPA:DHA 1:1 inducedconcentration-dependent relaxations of coronary artery rings withendothelium whereas only small relaxations were obtained in thosewithout endothelium contracted with U46619 (FIG. 4). The relaxations toEPA:DHA 1:1 was observed at volumes greater than 0.01% v/v and theyreached about 75% at 0.4% v/v (FIG. 4). In addition, the omega-3 fattyacid preparation EPA:DHA 6:1 also induced endothelium-dependentrelaxations which were more potent than those induced by EPA:DHA 1:1(FIG. 4). Relaxations to EPA:DHA 6:1 started at 0.01% v/v and theyreached about 98% at 0.4% v/v (FIG. 4). These findings indicate that theomega-3 fatty acid preparation EPA:DHA 6:1 is more effective to induceendothelium-dependent relaxations of coronary artery rings than theEPA:DHA 1:1 preparation. Thereafter, all subsequent experiments wereperformed with the omega-3 fatty acid preparation EPA:DHA 6:1.

It was determined that the omega-3 fatty acid preparation EPA:DHA 6:1induces endothelium-dependent relaxations involving both NO and EDHF.

Previous studies have indicated that EPA and DHA induce relaxation ofcoronary artery rings by a mechanism mainly endothelium-dependent andsensitive to inhibitors of the formation of NO and EDHF (Omura et al.,2001). Therefore, a study to determine whether the endothelium-dependentrelaxations induced by omega-3 fatty acid formulations having an EPA:DHAratio of about 6:1 according to the present invention (referred to asEpA:DHA 6:1 herein) involve NO and EDHF was undertaken. Theendothelium-dependent relaxation to EPA:DHA 6:1 was not significantlyaffected by inhibitors of the EDHF component, TRAM 34 and apamin(inhibitors of Ca²⁺-dependent potassium channels of intermediate and lowconductance IKCa and SKCa, respectively, FIG. 5). In contrast,relaxations were partially inhibited, but in a statistically significantamount, by L-NA (a competitive inhibitor of eNOS), indicating theinvolvement of NO (FIG. 5). In addition, the combination of L-NA plusTRAM 34 and apamin abolished the endothelium-dependent relaxation toEPA:DHA 6:1 (FIG. 5). Altogether, these findings indicate that EPA:DHA6:1 induces endothelium-dependent relaxations which are mediatedpredominantly by NO and also, to a lesser extent, by EDHF.

Several studies have shown that relaxations mediated by NO in responseto polyphenols derived from grapes involve the redox-sensitiveSrc/PI3-kinase/Akt pathway (Anselm et al., 2007; Ndiaye et al., 2005).Therefore, it was decided to determine whether this pathway is involvedin NO-mediated relaxations to EPA:DHA 6:1. In order to selectively studythe NO component, all experiments were conducted in the presence ofinhibitors of the EDHF component (Apamin+TRAM 34) and the formation ofvasoactive prostanoids (indomethacin). The relaxation induced by EPA:DHA6:1 was significantly reduced by PP2 (an inhibitor of Src kinase, FIG.6) and wortmannin (an inhibitor of PI3-kinase, FIG. 6). Furthermore, therelaxations to EPA:DHA 6:1 were shifted to the right by the membranepermeant analog of SOD, MnTMPyP and catalase (PEG-catalase) and bynative SOD and catalase (FIG. 7) in a statistically significant amount.Altogether, these findings suggest that Src kinase and the PI3-kinasemediate the stimulatory signal of EPA:DHA 6:1 to eNOS via aredox-sensitive mechanism.

To obtain direct evidence that EPA:DHA 6:1 is able to activate thePI3-kinase/Akt pathway leading to eNOS activation, cultured coronaryartery endothelial cells were exposed to EPA:DHA 6:1 up to 6 hours andthe level of phosphorylated Akt and eNOS was determined using Westernblot. The data indicate that EPA:DHA 6:1 increased the level ofphosphorylation of Akt and eNOS starting at 15 min and that this effectpersists until 6 h (FIG. 8A and FIG. 8B). The level of total eNOSexpression remained unaffected by the EPA:DHA 6:1 treatment (FIG. 8A).In addition, the stimulatory effect of EPA:DHA 6:1 on phosphorylation ofAkt and eNOS was inhibited by MnTMPyP, PEG-catalase and by native SODand catalase (FIG. 8A). Thus, these data provide direct evidence thatEPA:DHA 6:1 activate eNOS via a redox-sensitive mechanism

TABLE 5 Comparative Capsule Contents VASCAZEN ™ vs. German Omega-3 OTCBrands Omega-3 (mg/ Vitamin E EPA + DHA Weigt/Capsule %) per Vitamin E(in EPA DHA (in Product (mg) Capsule (mg)/Capsule %)/Capsule(mg)/Capsule (mg)/Capsule %)/Capsule ABTEI 1767 390/22.1 15 0.85 230 16022 TETESEPT ® 1350 350/25.9 15 1.1 180 120 22.2 DOPPELHERZ ® 1300300/23.1 12 0.92 180 120 23.1 SCHAEBENS 1450 500/34.5 10 0.07 n/a (500mg n/a — VEGETAL linolenic acid) SCHAEBENS 900  195/21.67 10 1.1 117 7821.7 FISH OIL OPTISANA ® 708 130/18.4 6 0.85 80 50 18.4 (LIDL)VASCAZEN ™ 1000 900/90% 2 0.2 680 110 79 Omega-3 in % signifies totalomega-3 in % of total fatty acids as EE (ethyl esters)

Now referring to FIGS. 9-12, these figures help to illustrate theimportance of both the purity of and the presence of additives in theformulation, respectively in providing a maximal relaxation response.For the purpose of this discussion, omega-3 purity was defined as thepercentage of the sum of EPA+DHA per capsule. The use of indomethacin asa determinant of the relaxation effect is based upon the followingexplanation. In some blood vessels vasorelaxing prostanoids such asprostacyclin have been identified as an endotheliun-derived vasorelaxingfactor. These vasorelaxing prostanoids are generated from the metabolismof arachidonic acid by cyclooxygenase-1 (COX-1). Indomethacin is aninhibitor of COX-1 and thus will prevent the formation of vasorelaxingprostanoids. The magnitude of the endothelium-dependent relaxation isdependent on the purity of the formulation (FIG. 9) and on the EPA:DHAratio (FIG. 4). In addition, the EPA:DHA 6:1 formulation caused similarendothelium-dependent relaxation as the OTC Omega-3 product TETESEPT™with an omega-3 purity (as defined above) of 22.2% as compared to thatof the EPA:DHA 6:1 formulation of 75.1% and was much more effective thanthe other OTC Omega-3s tested (ABTEI LACHSÖL™ 1300, DOPPELHER®,SCHAEBENS™ and OPTISANA™ (FIG. 11A). The endothelium-dependentrelaxation induced by VASCAZEN™ (as an example of EPA:DHA 6:1) is notaffected by indomethacin at 10 μM. In contrast, the relaxation inducedby TETESEPT™ which was similar to that of EPA:DHA 6:1 was significantlyreduced by indomethacin (FIGS. 11A and B). Endothelium-dependentrelaxations induced by SCHAEBENS™ and OPTISANA™ were markedly reducedand those to ABTEI™ and DOPPELHER® were slightly reduced (FIGS. 11A andB). These data further indicate that the indomethacin-sensitiverelaxation of the OTC Omega-3s cannot be attributed to EPA and DHA norto its relative concentration ratio but most likely to the presence ofadditives such as Vitamin E (alpha-tocopherol), see Table 5. Indeed, thevitamin E content of EPA:DHA 6:1 is 0.2% whereas that of OTC Omega-3formulations varies between 0.85 and 1.1% (Table 5). The importance ofthe vitamin E additive effect is further suggested by the fact thatTETESEPT™ has a more than fivefold higher vitamin E content than that ofthe EPA:DHA 6:1 formulation. Therefore, the selective inhibitory effectof indomethacin induced upon the TETESEPT™ but not upon the EPA:DHA 6:1is most likely explained by the more than fivefold higher vitamin Econtent per capsule. Vitamin E has been shown to causeendothelium-dependent relaxation which is inhibited by indomethacin (Wuet al., J Nutr. 135: 1847-1853, 2005). Both omega-3 purity andadditives, contribute to the endothelium-dependent relaxation observedwith Omega-3 products. This is further illustrated by comparing therelaxation induced by the EPA:DHA 6:1 formulation to that of theMETAGENICS™ EPA-DHA 6:1 formulation. Indeed, the latter is markedlyinhibited by indomethacin as compared to the former (FIG. 12). Thus, inthe presence of indomethacin, the relaxation observed in the presence ofOmega-3 products is clearly dependent on omega-3 purity. Theseexperiments underscore the sustained (greater than 6 hours) vasodilatoryeffect achieved due to the unique ratio and omega-3 purity of the novelEPA:DHA 6:1 product of the present invention. The combination of the 6:1ratio coupled with the absence of exogenous impurities in the presentinvention lead to an indomethacin independent vasodilatory effect whencompared to either EPA or DHA alone, EPA:DHA 1:1 or to a 6:1 productwhich contains exogenous impurities (see FIGS. 4,9,11,12 and 13).

These findings indicate that omega-3 fatty acid preparations are potentendothelium-dependent vasodilators and that this effect is dependent onthe ratio and the omega-3 purity of EPA and DHA within the capsule. Theyfurther suggest that omega-3 fatty acids activate eNOS via aredox-sensitive PI3-kinase/Akt pathway leading to changes in thephosphorylation level of eNOS as illustrated in FIG. 14.

Experiment

Physicochemical Characterization and the Kinetic Equilibrium SolubilityComparison Between VASCAZEN™, OMAX3™, and OMEGABRITE™

It is well known that Omega-3 products vary dramatically in theirbioavailability. While slight variations in bioavailability aregenerally not of significance for casual users, whose desire is toingest these products for maintenance and/or preventive care, a moreprecise dosing is necessary for therapeutic efficacy. Further studieshave indicated the value of ingesting Omega-3 products of relativelyhigh purity. Brhyn et al, “Prostaglandins, Leukotrienes and EssentialFatty Acids”, 75 (2006) 19-24, demonstrated that the concentration ofOmega-3 fatty acids had independent effects on the uptake and outcomesduring short-term administration.

The Omega-3 formulation of the instant invention has an EPA/DHA ratio ofabout 6:1 (5.7:1 to 6.3:1) and greater than 90% purity. As illustratedherein, studies have shown this product to be superior in the treatmentof deficiencies in Omega-3, and thereby a superior product for thetreatment of cardiovascular disease in this patient population. In orderto determine if the demonstrated effects are a result of a novel andintrinsic property of the formulation, or alternatively are apredictable outgrowth of the use of a high purity (greater than 90%)EPA/DHA formulation, that is EPA/DHA ratio dependent, a testing protocolwas undertaken utilizing three commercially available Omega-3 ethylester products of high purity having differing ratios of EPA/DHA. Theproducts selected were the Omega 3 formulation of the instant invention,VASCAZEN™ (EPA/DHA=about 6:1), OMAX3™ (EPA/DHA=about 4:1), andOMEGABRITE™ (EPA/DHA=about 7:1). Test criteria were designed toelucidate the bioavailability of each formulation.

VASCAZEN™ (EPA/DHA ratio 6:1), OMAX3™ (EPA/DHA ratio 4:1) andOMEGABRITE™ (EPA/DHA ratio 7:1) are commercially available formulatedOmega 3 fish oil products, which are generally differentiated byreferencing their stated EPA/DHA ratios. Skilled artisans have theorizedthat differences in their efficacy and bioavailability may bepredictable and directly attributable to variations in the empiricalEPA/DHA ratio. The present inventors have determined that, surprisingly,this is not the case. On the contrary, the VASCAZEN™ formulation of theinstantly disclosed invention has unique and unexpected properties,which do not correlate to the formulation's intrinsic EPA/DHA ratio.

As will be demonstrated in the following experimental analyses, nocorrelation or linear relationship was found between the varying EPA/DHAratios of the three different formulations and their intrinsic kineticsolubility profile, which is a measure of their bioavailability. This isan unexpected finding, and may be explained by the fact that these threeformulations differ not only by their ratios but, and most importantly,by the uniqueness of their individual qualitative and quantitativecomponents.

Contrary to what a skilled artisan might have predicted based uponalterations in the empirical ratios of EPA/DHA, the instantly disclosedVASCAZEN™ formulation demonstrates unique properties with regard tovasodilation which are counter-intuitive to what might otherwise havebeen expected by observing only the EPA/DHA ratio.

In order to demonstrate the uniqueness of the poly-unsaturated fattyacid (Omega-3) formulation of the present invention, a physicochemicalcharacterization of Omega-3 formulations was undertaken. Thischaracterization analyzed the thermodynamic Kinetic and Equilibriumsolubility of the selected products—VASCAZEN™, available from PivotalTherapeutics; OMAX3™, available from Prevention Pharmaceuticals; andOMEGABRITE™, available from Omega Natural Science.

At present, bioequivalence of formulated active pharmaceuticalingredients (APIs) is generally done by measuring C_(Max) (Maximum SerumConcentration) and AUC (Area Under the Curve) in accordance with FDAguidelines. These measurements are cumulative measurements of APIs inbiological fluids, e.g. urine, plasma, or serum. They do not measure thechange in solubilization of varying amounts of APIs over time.

With regard to unformulated APIs, their cumulative solubilization invitro is determined by either Log P or Log D measurements, reflectingthe octanol/water partition coefficients of non-ionized or ionized APIs,respectively. According to established Log P measurement technologiessuch as ALOGPS, one would expect a linearity of kinetic solubility,based upon C_(MAX) and AUC values, when combining various ratios of pureEPA and DHA.

An alternative technology for measuring bioequivalence and IVIVC (invitro in vivo correlation) profiles is the SuperSol 1000 system,available from PREVENTOR, μTBC GmbH, Pfungstadt, Germany. The SuperSol1000 technology is used routinely for investigating differences insolubilization kinetics in a non-cumulative manner, and has become astandard for determining bioequivalence of generic formulated APIs. Thesensitivity and specificity of the SuperSol 1000 system enable theidentification of differences in solubilization kinetics of formulationswith identical or similar molar API/excipient ratios and provides thecapability of predicting API pharmacokinetic parameters such as C_(MAX)and AUC.

Detailed Experiment

The products were chosen with the objective of ascertaining a Kineticsolubility comparison between Omega-3-acid ethyl ester capsules of >90%purity containing different EPA/DHA ratios, e.g., Vascazen™ (EPA/DHAratio 6:1), Omax3™ (EPA/DHA ratio 4:1) and OmegaBrite™ (EPA/DHA ratio7:1) using thermodynamic kinetic and equilibrium SuperSol 1000 singlerun screening solubility analysis. Given the extremely low aqueoussolubility of Omega-3-acid ethyl esters, an aqueous solution of 2.5%EtOH was used in order to generate a sufficient base line solubility toallow for subsequent kinetic measurements of the solubilization processof each formulation. A sample volume of 350 μl was injected into themeasurement column at 37° C.

DEFINITIONS

The following parameters were measured:

“Early Kinetic Solubility” or “Early Stage Kinetic Solubility” isunderstood to refer to the solubility kinetics measured in the timeperiod prior to achieving C_(MAX).

“Late Kinetic Solubility” or “Late Stage Kinetic Solubility” isunderstood to refer to the solubility kinetics measured subsequent toattaining C_(MAX).

t_([MSS]) is defined as: Time from start of analysis to MaximumSolubilization Speed (min)C_([MSS]) is defined as: Early Kinetic Solubility as expressed asconcentration at Maximum Solubilization Speed (mg·l⁻¹)C_([Eq]) is defined as: Late Kinetic Solubility as expressed asConcentration at Equilibrium Kinetic Solubility (mg·l⁻¹)t_([Eq]) is defined as: Time from start of analysis to EquilibriumKinetic Solubility (min)ΔC[C_([Eq])−C_([MSS])] is defined as: Difference in ConcentrationBetween Early and Late Kinetic Solubility as defined above (mg·l⁻¹)Δt[t_([Eq])−t_([MSS])] is defined as: Difference in Time Between Earlyand Late Kinetic Solubility Endpoints (min)MSS is defined as: Maximum Solubilization Speed (mg·l⁻¹·min⁻¹) derivedas C_([MSS])/t_([MSS]). This is the earliest kinetic solubilityindicator for APIs and unformulated APIs.ISI is defined as: Intrinsic Solubility Index derived asΔC[C_(Eq)−C_(MSS])/Δt[t_(Eq)−t_(MSS)]KSR is defined as: Kinetic Solubility Ratio derived asC_([MSS])/C_([Eq]) and is an in vitro parameter measured by the Supersol1000 technology which correlates to both C_(MAX) and AUC. In order tocompare the sustained release profiles of the three formulations asreflected by AUC in vivo, KSR was measured.

The results of the Supersol 1000 analyses of the VASCAZEN™, OMAX3™ andOMEGABRITE™ formulations are summarized in Table 6.

TABLE 6 FORMULATION MSS t_([MSS]) C_([MSS]) C_([Eq]) T_([Eq])ΔC_([CEq−CMSS]) Δt_([tEq−tMSS]) ISI KSR Vascazen ™ (6:1)* 323.9 2:17323.9 513.8 8:25 189.9 6:08 31.2 0.63 Omax3 ™ (4:1)* 371.4 2:75 371.4627.8 8:42 256.4 5:67 45.2 0.59 OmegaBrite ™ (7:1)* 200.1 1:96 200.1372.8 8:33 172.7 6:37 27.1 0.54 *(EPA/DHA Ratio)

Unexpectedly, the values obtained by the SuperSol technology did notevidence any linearity. No correlation or linear relationship was foundbetween the varying EPA/DHA ratios of the three different formulationsand their intrinsic kinetic solubility profile. While not wishing to bebound to any particular theory or mechanism of operation, this may beexplained by the fact that these three formulations differ not only bytheir ratios, but also by their individual qualitative and quantitativecomponents.

When comparing equimolar concentrations of varying EPA/DHA ratios ofVascazen™, Omax3™ and OmegaBrite™ the similar ISI values found forVascazen™ and OmegaBrite™, 31.2 and 27.1, respectively reflect a closeEPA/DHA ratio (6:1 vs. 7:1) as opposed to the corresponding ISI ofOMAX3™, 45.2, that is significantly higher and demonstrates the morepronounced late solubilization of the latter having an EPA/DHA ratio of4:1 and a higher composite log P than mixtures with a higher EPA/DHAratio.

The present results are further interpreted in view of the different logP values of EPA and DHA when incorporated into formulations ofpharmaceutical grade as well as the qualitative and quantitativepresence of other n-3 and n-6 ingredients present. The lower the Log Pvalue, the higher the cumulative solubility of the API. As reported byTetko I V et al, ALOGPS, VCC Lab, Drug Discovery Today 10 (2005) Pp.1497-1500, EPA has both a lower theoretical (6.53) and experimental LogP than DHA (6.83) indicative of a slightly lower lipophilicity andsolvatation energy. Since the thermodynamic late kinetic solubilitykinetics are correlated with log P this signifies that the higher thelog P the faster the late solubilization kinetics measured.

The differences in early kinetic solubility between VASCAZEN™ andOMEGABRITE™, however, as reflected by KSR and MSS, are linked neither tolog P nor to the ratio itself. Thus, one can only conclude that theenhanced bioavailability of the VASCAZEN™ product is attributable to theother specific fatty acids present, e.g. the qualitative andquantitative nature of other non-EPA and non-DHA n-3 and n-6ingredients, as further illustrated in Table 7.

TABLE 7 AVG Range = C:

-pos (n = 9) SD AVG ± 2SD 2 × SD Common Name C18:3 N3 + C18:4 N3 AlphaLinolenic Acid + Stear

 Acid 3.33 0.06 3.21 3.45 0.12 C20:4 N6 Arac

onic Acid 3.26 0.11 3.04 3.48 0.22 C20:5 N3 (EPA) Eicosapentanoic Acid(EPA) 72.40 0.99 70.42 74.38 1.98 C22:5 N3 (DPA) Docosapen

Acid (

3) DPA 2.83 0.15 2.53 3.13 0.30 C22:6 N3 (DHA) Docod

hexanoic Acid (DHA) 12.90 0.29 12.32 13.48 0.58 % of total Fatty acidOmega-3 94.01 0.43 93.15 94.87 0.86 Omega-6 4.42 0.38 3.66 5.18 0.76 %of total Fatty acid EPA + DHA 85.22 1.30 82.62 87.82 2.60 EPA + DHA +DPA 88.06 1.17 85.72 90.40 2.34 18:3 n3-Alpha Linolenic Acid(ALA) 0.350.03 0.29 0.41 0.06 18:4 n3-Stea

donic acid (SDA) 2.98 0.06 2.86 3.10 0.12 ALA + SDA 3.33 0.06 3.21 3.450.12 % of Total Omega 3 EPA + DHA 90.66 1.20 88.26 93.06 2.40 EPA +DHA + DPA 93.66 1.14 91.38 95.94 2.28 18:3 n3-Alpha Linolenic Acid(ALA)0.37 0.04 0.29 0.45 0.08 18:4 n3-Stea

donic acid (SDA) 3.17 0.07 3.03 3.31 0.14 ALA + SDA 3.54 0.07 3.40 3.680.14

indicates data missing or illegible when filed

Several lots of the VASCAZEN™ formulation, as illustrated in Table 7,were analyzed. Three distinct formulation lots were analyzed intriplicate using different laboratories to yield 9 data points (n=9).This analysis yields numerical ranges, calculated as the average valueplus or minus two standard deviations (Avg±2 (SD)), which constituteacceptable variations in fatty acid contents for the instantformulation. Formulations within these ranges have been shown to havesuperior bioavailability, as illustrated by the instant physico-chemicalcharacterization. At the same time, these formulations exhibit a uniqueand desirable stable and sustained long-acting vasodilatory effect, ashas been previously demonstrated herein.

Based upon the data in Table 7, the instantly disclosed composition fortreatment or prophylaxis of risk factors for cardiovascular disease(CVD) and protection against sudden death in patients withcardiovascular disease may be defined as a mixture containing omega-3fatty acids including eicosapentaenoic acid (EPA), docosahexaenoic acid(DHA), and docosapentaenoic acid (DPA) wherein the weight ratio ofEPA:DHA is in the range of 5.7:1-6.3:1, and the amount of EPA+DHA in theformulation is about 82.62% to about 87.82% by weight of the total fattyacid content of the formulation, and about 88.26% to about 93.06% byweight of the total omega-3 content of the formulation; the formulationcontains from about 93.15% to about 94.87% by weight omega-3 fattyacids, and the sum of EPA, DHA and DPA are from about 85.72% to about87.82% by weight of the % of total fatty acids in the formulation, andfrom about 91.38% to about 95.94% by weight of the total % of omega-3present in the formulation; said formulation contains about 2.53% toabout 3.13% by weight of the % of total fatty acids in the formulationof DPA, about 3.04% to about 3.48% by weight of the % of total fattyacids in the formulation of arachidonic acid (AA), and about 3.21% toabout 3.45% by weight of the % of total fatty acids in the formulation,of omega-3 fatty acids having 18 carbon atoms, wherein said 18 carbonatom omega-3 fatty acids are alpha-linolenic acid (ALA) and stearidonicacid (SDA). The sum of ALA and SDA is about 3.40% to about 3.68% byweight of the total % of omega-3 present in the formulation.

The above data demonstrate that there is no linearity or trend tying thephysical characteristics of the test formulations to their EPA/DHAratios. Furthermore, the data demonstrate a higher bioavailability andsolubility for the VASCAZEN™ formulation, which supports the hypothesisthat the sustained vasodilation effects achieved by the VASCAZEN™product are attributable to the unique blend of fatty acids present, andresult in a formulation having heretofore unexpected characteristics.

All patents and publications mentioned in this specification areindicative of the levels of those skilled in the art to which theinvention pertains. All patents and publications are herein incorporatedby reference to the same extent as if each individual publication wasspecifically and individually indicated to be incorporated by reference.

It is to be understood that while a certain form of the invention isillustrated, it is not to be limited to the specific form or arrangementherein described and shown. It will be apparent to those skilled in theart that various changes may be made without departing from the scope ofthe invention and the invention is not to be considered limited to whatis shown and described in the specification and any drawings/figuresincluded herein.

One skilled in the art will readily appreciate that the presentinvention is well adapted to carry out the objectives and obtain theends and advantages mentioned, as well as those inherent therein. Theembodiments, methods, procedures and techniques described herein arepresently representative of the preferred embodiments, are intended tobe exemplary and are not intended as limitations on the scope. Changestherein and other uses will occur to those skilled in the art which areencompassed within the spirit of the invention and are defined by thescope of the appended claims. Although the invention has been describedin connection with specific preferred embodiments, it should beunderstood that the invention as claimed should not be unduly limited tosuch specific embodiments. Indeed, various modifications of thedescribed modes for carrying out the invention which are obvious tothose skilled in the art are intended to be within the scope of thefollowing claims.

1. A pharmaceutical formulation for treatment or prophylaxis of riskfactors for cardiovascular disease (CVD), protection against suddendeath in patients with cardiovascular disease, reduction of overallserum cholesterol levels, reductions in high blood pressure, increase inthe HDL:LDL ratio, and reduction of triglycerides comprising: a mixturecontaining omega-3 fatty acids including eicosapentaenoic acid (EPA),docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) wherein theweight ratio of EPA:DHA is in the range of 5.7:1-6.3:1, the formulationcontains about 90% or more by weight omega-3 fatty acids, and the EPA,DHA and DPA comprise about 82% by weight of the content of theformulation; and at least one azetidinone cholesterol absorptioninhibitor or pharmaceutically acceptable salt thereof or a combinationthereof.
 2. The formulation in accordance with claim 1 comprising about25 mg/g of DPA.
 3. The formulation in accordance with claim 1 furthercomprising about 30 mg/g of arachidonic acid (AA).
 4. The formulation inaccordance with claim 1 further comprising about 30 mg/g of one or moreomega-3 fatty acids having 18 carbon atoms.
 5. The formulation inaccordance with claim 5 wherein said one or more 18 carbon atom omega-3fatty acid is selected from the group consisting of alpha-linolenic acid(ALA), stearidonic acid (SDA) and combinations thereof.
 6. Theformulation in accordance with claim 1 wherein the omega-3 fatty acidsare in the form of ethyl esters and pharmaceutically acceptable saltsthereof.
 7. The formulation in accordance with claim 1 wherein theomega-3 fatty acids are in the form of triglycerides andpharmaceutically acceptable salts thereof.
 8. The formulation inaccordance with claim 1 wherein the omega-3 fatty acids are in the formof phospholipids and pharmaceutically acceptable salts thereof.
 9. Theformulation in accordance with claim 1 in a unit dosage form comprisingfrom about 645 to about 715 mg/gm EPA from about 105 to about 115 mg/gm,DHA and from about 22 to about 28 mg/gm, DPA.
 10. The formulation inaccordance with claim 1 in a unit dosage form comprising at least 680 mgEPA, at least 110 mg DHA and at least 25 mg DPA.
 11. The formulation inaccordance with claim 9 wherein the unit dosage form further includesabout 30 mg of AA.
 12. The formulation in accordance with claim 9wherein the unit dosage form further includes about 30 mg/g of omega-3fatty acids having 18 carbon atoms.
 13. The formulation in accordancewith claim 12 wherein said one or more 18 carbon atom omega-3 fatty acidis selected from the group consisting of alpha-linolenic acid (ALA),stearidonic acid (SDA) and combinations thereof.
 14. The formulation inaccordance with claim 9 wherein the formulation additionally comprises astabilizer.
 15. The formulation in accordance with claim 14 wherein thestabilizer is tocopherol in an amount of about 0.2%.
 16. The formulationin accordance with claim 9 wherein the unit dosage form may comprisetablets, capsules, pills, powders, granules, and oral solutions orsuspensions.
 17. The formulation in accordance with claim 16 wherein theunit dosage form is a gel or liquid capsule.
 18. A pharmaceuticalformulation for treatment or prophylaxis of risk factors forcardiovascular disease (CVD), protection against sudden death inpatients with cardiovascular disease, reduction of overall serumcholesterol levels, reductions in high blood pressure, increase in theHDL:LDL ratio, and reduction of triglycerides comprising: a mixturecontaining omega-3 fatty acids including eicosapentaenoic acid (EPA),docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) wherein theweight ratio of EPA:DHA is in the range of 5.7:1-6.3:1; the formulationcontains about 90% or more by weight omega-3 fatty acids, and the EPA,DHA and DPA comprise about 82% by weight of the content of theformulation; said formulation contains about 25 mg/g of DPA, about 30mg/g of arachidonic acid (AA), and about 30 mg/g of one or more omega-3fatty acids having 18 carbon atoms, wherein said 18 carbon atom omega-3fatty acid is selected from the group consisting of alpha-linolenic acid(ALA), stearidonic acid (SDA) and combinations thereof; and at least oneazetidinone cholesterol absorption inhibitor or pharmaceuticallyacceptable salt thereof or a combination thereof.
 19. A pharmaceuticalformulation for treatment or prophylaxis of risk factors forcardiovascular disease (CVD), protection against sudden death inpatients with cardiovascular disease, reduction of overall serumcholesterol levels, reductions in high blood pressure, increase in theHDL:LDL ratio, and reduction of triglycerides comprising: a mixturecontaining omega-3 fatty acids including eicosapentaenoic acid (EPA),docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) wherein theweight ratio of EPA:DHA is in the range of 5.7:1-6.3:1, the amount ofEPA+DHA in the formulation is about 82.62% to about 87.82% by weight ofthe total fatty acid content of the formulation, and about 88.26% toabout 93.06% by weight of the total omega-3 content of the formulation;the formulation contains from about 93.15% to about 94.87% by weightomega-3 fatty acids; the sum of EPA, DHA and DPA are from about 85.72%to about 87.82% by weight of the total fatty acids in the formulation,and from about 91.38% to about 95.94% by weight of the total omega-3present in the formulation; said formulation contains about 2.53% toabout 3.13% by weight of the total fatty acids in the formulation ofDPA, about 3.04% to about 3.48% by weight of the total fatty acids inthe formulation of arachidonic acid (AA), and about 3.21% to about 3.45%by weight of the total fatty acids in the formulation, of omega-3 fattyacids having 18 carbon atoms, wherein said 18 carbon atom omega-3 fattyacids are alpha-linolenic acid (ALA) and stearidonic acid (SDA); andwherein the sum of ALA and SDA is about 3.40% to about 3.68% by weightof the total omega-3 present in the formulation; and at least oneazetidinone cholesterol absorption inhibitor or pharmaceuticallyacceptable salt thereof or a combination thereof.
 20. A process for thetreatment of, or prophylaxis of risk factors for, cardiovascular disease(CVD), protection against sudden death in patients with cardiovasculardisease, reduction of overall serum cholesterol levels, reductions inhigh blood pressure, increase in the HDL:LDL ratio, and reduction oftriglycerides and homocysteine levels comprising: identifying a patientpopulation that exhibits deficiencies in omega-3 fatty acids, andadministering to said patient population a formulation in accordancewith claim 1; whereby a therapeutic effect is achieved.
 21. A processfor the treatment of, or prophylaxis of risk factors for, cardiovasculardisease (CVD), protection against sudden death in patients withcardiovascular disease, reduction of overall serum cholesterol levels,reductions in high blood pressure, increase in the HDL:LDL ratio, andreduction of triglycerides and homocysteine levels comprising:identifying a patient population that exhibits deficiencies in omega-3fatty acids, and administering to said patient population a formulationin accordance with claim 18; whereby a therapeutic effect is achieved.22. A process for the treatment of, or prophylaxis of risk factors for,cardiovascular disease (CVD), protection against sudden death inpatients with cardiovascular disease, reduction of overall serumcholesterol levels, reductions in high blood pressure, increase in theHDL:LDL ratio, and reduction of triglycerides and homocysteine levelscomprising: identifying a patient population that exhibits deficienciesin omega-3 fatty acids, and administering to said patient population aformulation in accordance with claim 19; whereby a therapeutic effect isachieved.
 23. A process in accordance with claim 1 for achieving anindomethacin-independent sustained vasodilatory effect comprising:identifying a patient population that exhibits deficiencies in omega-3fatty acids; and administering to said patient population a formulationin accordance with claim 1; whereby a therapeutic effect is achieved.24. A process in accordance with claim 18 for achieving anindomethacin-independent sustained vasodilatory effect comprising:identifying a patient population that exhibits deficiencies in omega-3fatty acids; and administering to said patient population a formulationin accordance with claim 18; whereby a therapeutic effect is achieved.25. A process in accordance with claim 19 for achieving anindomethacin-independent sustained vasodilatory effect comprising:identifying a patient population that exhibits deficiencies in omega-3fatty acids; and administering to said patient population a formulationin accordance with claim 19; whereby a therapeutic effect is achieved.